Search results for "Growth factors"

showing 10 items of 118 documents

Emerging Therapeutic Strategies for Traumatic Spinal Cord Injury

2020

Spinal cord injury (SCI) is a debilitating neurologic condition with tremendous socioeconomic impact on affected individuals and the health care system. The treatment of SCI principally includes surgical treatment and marginal pharmacologic and rehabilitation therapies targeting secondary events with minor clinical improvements. This unsuccessful result mainly reflects the complexity of SCI pathophysiology and the diverse biochemical and physiologic changes that occur in the injured spinal cord. Once the nervous system is injured, cascades of cellular and molecular events are triggered at varying times. Although the cascade of tissue reactions and cell injury develops over a period of days …

Nervous systemmedicine.medical_specialtyCordmedicine.medical_treatmentSpinal cord injuryRegenerative MedicineMesenchymal Stem Cell TransplantationNeuroprotection03 medical and health sciences0302 clinical medicineNeural Stem CellsGlyburideGranulocyte Colony-Stimulating FactormedicineHumansHypoglycemic AgentsIntensive care medicineErythropoietinSpinal cord injurySpinal Cord InjuriesNeuronal PlasticityRehabilitationCombination treatmentsHepatocyte Growth Factorbusiness.industryNeurological RehabilitationDecompression SurgicalSpinal cordmedicine.diseaseNeuroregenerationNeuroprotectionClinical trialFibroblast Growth FactorsClinical trialmedicine.anatomical_structure030220 oncology & carcinogenesisIntercellular Signaling Peptides and ProteinsSurgeryNeuroregenerationSchwann CellsNeurology (clinical)business030217 neurology & neurosurgeryStem Cell TransplantationWorld Neurosurgery
researchProduct

Sequential Hepatogenic Transdifferentiation of Adipose Tissue-Derived Stem Cells: Relevance of Different Extracellular Signaling Molecules, Transcrip…

2009

Adipose tissue contains a mesenchymal stein cell (MSC) population Known as adipose-derived stein cells (ASCs) capable of differentiating into different cell types. Our aim was to induce hepatic transdifferentiation of ASCs by sequential exposure to several combinations of cytokines, growth factors, and hormones. The most efficient hepatogenic protocol includes fibroblastic growth factors (FGF) 2 and 4 and epidermal growth factor (EGF) (step 1), hepatocyte growth factor (HGF), FGF2, FGF4, and nicotinamide (Nic) (step 2), and oncostatin M (OSM), dexamethasone (Dex), and insulin-tranferrin-selenium (step 3). This protocol activated transcription factors [GATA6, Hex, CCAAT/enhancer binding prot…

NiacinamideCellular differentiationBiomedical Engineeringlcsh:MedicineOncostatin MBiologyDexamethasoneSeleniumEpidermal growth factorEnhancer bindingHumansInsulinCells CulturedHepatocyte differentiationTransplantationHepatocyte Growth FactorGene Expression Profilinglcsh:RTransdifferentiationTransferrinMesenchymal Stem CellsHep G2 CellsCell BiologyFlow CytometryMolecular biologyCell biologyFibroblast Growth FactorsAdipose TissueHepatocyte Nuclear Factor 4Hepatocyte nuclear factor 4 alphaCell TransdifferentiationHepatocytesStem cellSignal TransductionTranscription FactorsAdult stem cellCell Transplantation
researchProduct

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO stud…

2014

Background: Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study. Patients and methods: 102 unresectable or metastatic BTC patients with histologically proven adenocarcinoma of gallbladder or intrahepatic bile ducts, Eastern Cooperative Oncology Group (ECOG) 0–2 were randomised to gemcitabine (1000 mg/m2 once weekly, first 7-weeks + 1-week rest followed by once 3-weeks + 1-week rest) plus sorafenib (400 mg twice daily) or placebo. Treatment continued until progression or unacceptable toxicity. Tumour samples were p…

OncologyMaleCancer ResearchAdvanced biliary tract cancerPDGFRβPhases of clinical researchHif1αKaplan-Meier Estimateurologic and male genital diseasesGastroenterologyDeoxycytidineMetastasisAntineoplastic Combined Chemotherapy Protocolsheterocyclic compoundsProspective StudiesLymph nodeAged 80 and overVascular Endothelial Growth FactorsMiddle AgedSorafenibBTCfemale genital diseases and pregnancy complicationsmedicine.anatomical_structureBiliary Tract NeoplasmsTreatment OutcomeOncologyAdenocarcinomaFemaleGallbladder NeoplasmsHand-Foot Syndromemedicine.drugSorafenibAdultNiacinamidemedicine.medical_specialtyPlaceboDisease-Free SurvivalDrug Administration ScheduleDouble-Blind MethodInternal medicinemedicineBiomarkers TumorHumansddc:610neoplasmsAgedbusiness.industryGallbladderPhenylurea Compoundsmedicine.diseaseVascular Endothelial Growth Factor Receptor-2Gemcitabinedigestive system diseasesGemcitabineChemokine CXCL12VEGFR-3VEGFR-2Bile Ducts IntrahepaticBile Duct Neoplasmsc-kitQuality of LifebusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Prognostic value of the immunohistochemical expression of vascular endothelial growth factors in malignant salivary gland neoplasms: a systematic rev…

2020

Background The immunohistochemical expression of vascular endothelial growth factor is a prognostic marker in several cancer types. In salivary gland tumors, the association between vascular endothelial growth factor and prognosis remains unclear. The purpose of this study was to perform a systematic review and meta-analysis to assess whether the immunohistochemical expression of vascular endothelial growth factor in patients with salivary gland neoplasms presents prognostic value. Material and Methods Immunohistochemical studies assessing the predictive value of vascular endothelial growth factor in salivary gland neoplasms were systematically reviewed using PubMed, Scopus, Embase, Cochran…

OncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyPerineural invasionReview03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineBiomarkers TumorsexHumansGeneral DentistryGrading (tumors)UNESCO:CIENCIAS MÉDICAStooth extractionOral Medicine and PathologySalivary glandbusiness.industryVascular Endothelial Growth FactorsHazard ratioCancer030206 dentistrymedicine.diseasePrognosisSalivary Gland NeoplasmsVascular endothelial growth factormolarVascular endothelial growth factor Amedicine.anatomical_structureOtorhinolaryngologychemistryImmunohistochemistrySurgeryNeoplasm Recurrence LocalbusinessthirdMedicina oral, patologia oral y cirugia bucal
researchProduct

Content of blood cell components, inflammatory cytokines and growth factors in autologous platelet-rich plasma obtained by various methods.

2022

BACKGROUND The evaluation of the efficacy of platelet-rich plasma (PRP) in clinical practice yields conflicting results and raises numerous controversies. This may be due to different concentrations of biologically active components in PRP obtained with the use of different methods of gravity separation. AIM To compare the content, repeatability and correlations between biologically active components in PRP obtained with four different commercial systems. METHODS From a whole blood sample of each of 12 healthy male volunteers, 4 PRP samples were prepared using 4 different commercial kits [Arthrex Autologous Conditioned Plasma (ACP), Mini GPS III, Xerthra, Dr. PRP] in accordance with the ins…

Orthopedics and Sports MedicinePlatelet-rich plasma; Cytokines; Chemokines; Growth factorsWorld journal of orthopedics
researchProduct

Stem cell-secreted factor therapy regenerates the ovarian niche and rescues follicles.

2021

Background Ovarian senescence is a normal age-associated phenomenon, but increasingly younger women are affected by diminished ovarian reserves or premature ovarian insufficiency. There is an urgent need for developing therapies to improve ovarian function in these patients. In this context, previous studies suggest that stem cell–secreted factors could have regenerative properties in the ovaries. Objective This study aimed to test the ability of various human plasma sources, enriched in stem cell–secreted factors, and the mechanisms behind their regenerative properties, to repair ovarian damage and to promote follicular development. Study Design In the first phase, the effects of human pla…

Ovarian CortexOvaryBone Marrow CellsPrimary Ovarian InsufficiencyPremature ovarian insufficiencyHematopoietic Cell Growth Factors03 medical and health sciencesMicePlasma0302 clinical medicineOvarian FollicleMice Inbred NODGranulocyte Colony-Stimulating FactorMedicineAnimalsHumans030212 general & internal medicinePlatelet activationOvarian ReserveStem Cell Factor030219 obstetrics & reproductive medicinebusiness.industryCell growthStem CellsOvaryInfant NewbornObstetrics and GynecologyBone Marrow Stem CellCell cycleFetal BloodDisease Models Animalmedicine.anatomical_structureCancer researchHeterograftsFemaleStem cellbusinessAmerican journal of obstetrics and gynecology
researchProduct

Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2.

2013

Background: Prostaglandin E2 (PGE(2)), the main metabolite of cyclooxygenase (COX), is a well-known anti-fibrotic agent. Moreover, myofibroblasts expressing alpha-smooth muscle actin (alpha-SMA), fibroblast expansion and epithelial-mesenchymal transition (EMT) are critical to the pathogenesis of idiopathic pulmonary fibrosis (IPF). Our aim was to investigate the expression of COX-2 and PGE(2) in human lung myofibroblasts and establish whether fibroblast-myofibroblast transition (FMT) and EMT are associated with COX-2 and PGE(2) down-regulation. Methods: Fibroblasts obtained from IPF patients (n = 6) and patients undergoing spontaneous pneumothorax (control, n = 6) and alveolar epithelial ce…

PathologyPulmonologyMetaboliteImmunofluorescencelcsh:MedicineBiochemistrychemistry.chemical_compoundIdiopathic pulmonary fibrosisMolecular Cell BiologyPulmonary fibrosisProstaglandin E2Myofibroblastslcsh:ScienceLungCells CulturedFisiologia cel·lularMultidisciplinarybiologyFibrosi pulmonarrespiratory systemExtracellular Matrixmedicine.anatomical_structureCytokinesMedicinelipids (amino acids peptides and proteins)Immunohistochemical AnalysisMyofibroblastResearch ArticleSignal Transductionmedicine.drugmedicine.medical_specialtyEpithelial-Mesenchymal TransitionImmunologyInterstitial Lung DiseasesDinoprostonePulmonary fibrosisTransforming Growth Factor beta1ImmunofluorescènciaGrowth FactorsCell Line TumormedicineHumansEpithelial–mesenchymal transitionFibroblastBiologyCell Proliferationlcsh:RProteinsEpithelial Cellsmedicine.diseaseActinsIdiopathic Pulmonary Fibrosisrespiratory tract diseasesGene Expression RegulationchemistryCyclooxygenase 2Immune SystemCase-Control StudiesImmunologic Techniquesbiology.proteinCancer researchClinical Immunologylcsh:QCyclooxygenaseBiomarkersPLoS ONE
researchProduct

Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease

2001

BACKGROUNDHirschsprung disease (HSCR) is a frequent congenital disorder with an incidence of 1 in 5000 live births, characterised by the absence of parasympathetic intramural ganglion cells in the hindgut resulting in intestinal obstruction in neonates and severe constipation in infants and adults. Intestinal neuronal dysplasia (IND) shares clinical features with HSCR but the submucosal parasympathetic plexus is affected. IND has been proposed as one of the most frequent causes of chronic constipation and is often associated with HSCR.METHODSWe examined 29 patients diagnosed with sporadic HSCR, 20 patients with IND, and 12 patients with mixed HSCR/IND for mutations in the coding regions of …

Pathologymedicine.medical_specialtyGlial Cell Line-Derived Neurotrophic Factor ReceptorsHirschsprung diseaseMUTATION ANALYSISNerve Tissue ProteinsTYROSINE KINASEEDNRBArticleExonGermline mutationProto-Oncogene ProteinsNEUROTROPHIC FACTOR GDNFmedicineGlial cell line-derived neurotrophic factorDrosophila ProteinsHumansGlial Cell Line-Derived Neurotrophic FactorNerve Growth FactorsAlleleintestinal neuronal dysplasiaAllelesPolymorphism Single-Stranded ConformationalIntestinal neuronal dysplasiabiologyReceptors EndothelinSHAH-WAARDENBURG SYNDROMEProto-Oncogene Proteins c-retENDOTHELIN-B-RECEPTORMULTIGENIC INHERITANCEGastroenterologyReceptor Protein-Tyrosine KinasesSequence Analysis DNAGERMLINE MUTATIONSbiochemical phenomena metabolism and nutritionPROTOONCOGENEmedicine.diseasePHENOTYPIC-EXPRESSIONGDNFPedigreeProto-Oncogene Proteins c-retDysplasiaCase-Control StudiesMutationbiology.proteinLIGANDRETCongenital disorderEDN3
researchProduct

Dextran sulfate sodium leads to chronic colitis and pathological angiogenesis in Endoglin heterozygous mice

2010

Pathological angiogenesis is an intrinsic component of chronic intestinal inflammation, which results in remodeling and expansion of the gut microvascular bed. Endoglin is essential for endothelial cell function and physiological angiogenesis. In this study we investigated its potential role in the regulation of inflammation by testing the response of Endoglin heterozygous (Eng(+/-)) mice to experimental colitis.C57BL/6 Eng(+/-) and littermate control mice drank water supplemented with 3% dextran sulfate sodium (DSS) for 5 days and were monitored for up to 26 days for clinical signs of colitis. Inflammation, crypt damage, and angiogenic index were scored on histological sections of distal c…

Pathologymedicine.medical_specialtyHeterozygoteAngiogenesisColonVascular permeabilityInflammatory bowel diseaseArticleNeovascularizationCapillary Permeabilitychemistry.chemical_compoundMicemedicineImmunology and AllergyAnimalsColitisAcute colitisNeovascularization Pathologicbusiness.industryVascular Endothelial Growth FactorsDextran SulfateGastroenterologyEndoglinIntracellular Signaling Peptides and ProteinsEndoglinmedicine.diseaseColitisVascular endothelial growth factorMice Inbred C57BLDisease Models AnimalchemistryAcute Diseasemedicine.symptombusinessAngiopoietins
researchProduct

BDNF, but not NT-4, is necessary for normal development of Meissner corpuscles.

2005

Abstract Meissner corpuscles are rapidly adapting cutaneous mechanoreceptors depending for development on TrkB expressing sensory neurons, but it remains to be established which of the known TrkB ligands, BDNF or NT-4, is responsible of this dependence. In this study we analyze Meissner corpuscles in the digital pads of mice with target mutations in the genes encoding for either BDNF or NT-4, using immunohistochemistry and transmission-electron microscopy, and they were identified based on their morphology and expression of S100 protein. All wild-type animals as well as NT-4 −/− animals and BDNF and NT4 heterozygous animals have Meissner corpuscles that are normal in number and size. Howeve…

Pathologymedicine.medical_specialtyRatónTropomyosin receptor kinase BLigandsS100 proteinMicemedicineAnimalsReceptor trkBNerve Growth FactorsBrain-derived neurotrophic factorMice KnockoutbiologyChemistryGeneral NeuroscienceBrain-Derived Neurotrophic FactorCell biologyMechanoreceptorMice Inbred C57BLmedicine.anatomical_structurenervous systemMeissner Corpusclebiology.proteinImmunohistochemistryMechanoreceptorsNeurotrophinNeuroscience letters
researchProduct